LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 102 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2021. The put-call ratio across all filers is 2.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $47,295 | +3.4% | 31,530 | 0.0% | 0.01% | -18.2% |
Q4 2022 | $45,719 | +8.9% | 31,530 | -14.8% | 0.01% | -8.3% |
Q3 2022 | $42,000 | -46.8% | 37,008 | -25.6% | 0.01% | -40.0% |
Q2 2022 | $79,000 | -17.7% | 49,736 | -20.4% | 0.02% | -13.0% |
Q1 2022 | $96,000 | -39.6% | 62,488 | -4.0% | 0.02% | -43.9% |
Q4 2021 | $159,000 | -11.2% | 65,069 | -7.9% | 0.04% | -22.6% |
Q3 2021 | $179,000 | -2.2% | 70,625 | +10.0% | 0.05% | -18.5% |
Q2 2021 | $183,000 | +20.4% | 64,232 | -0.6% | 0.06% | -11.0% |
Q1 2021 | $152,000 | +28.8% | 64,614 | -3.4% | 0.07% | +5.8% |
Q4 2020 | $118,000 | +81.5% | 66,917 | -4.2% | 0.07% | +40.8% |
Q3 2020 | $65,000 | +25.0% | 69,874 | +17.2% | 0.05% | -3.9% |
Q2 2020 | $52,000 | – | 59,597 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 34,935,485 | $40,874,517 | 3.42% |
Defender Capital, LLC. | 5,093,535 | $5,959,436 | 2.41% |
Raffles Associates | 1,536,946 | $1,798,230 | 2.10% |
Prescott General Partners LLC | 1,851,851 | $2,166,666 | 0.18% |
DAFNA Capital Management LLC | 140,000 | $163,800 | 0.05% |
Fort Sheridan Advisors LLC | 83,931 | $98,199 | 0.03% |
Beirne Wealth Consulting Services, LLC | 45,000 | $52,650 | 0.03% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $914,666 | 0.02% |
ETF MANAGERS GROUP, LLC | 353,991 | $414,169 | 0.02% |
Straight Path Wealth Management | 16,200 | $18,954 | 0.02% |